Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) traded up 3.2% during trading on Wednesday . The company traded as high as $11.92 and last traded at $11.90, with a volume of 81,686 shares trading hands. The stock had previously closed at $11.53.

A number of equities research analysts have recently commented on the company. Mizuho restated a “buy” rating on shares of Sucampo Pharmaceuticals in a research report on Wednesday, May 4th. WallachBeth Capital upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research report on Thursday, May 5th. Guggenheim restated a “buy” rating and set a $29.00 target price on shares of Sucampo Pharmaceuticals in a research report on Wednesday, May 4th. Maxim Group restated a “buy” rating on shares of Sucampo Pharmaceuticals in a research report on Monday, July 11th. Finally, Roth Capital restated a “buy” rating on shares of Sucampo Pharmaceuticals in a research report on Tuesday, July 12th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $21.00.

The firm has a 50-day moving average price of $11.16 and a 200-day moving average price of $11.69. The firm has a market cap of $512.41 million and a price-to-earnings ratio of 23.80.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its earnings results on Wednesday, May 4th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.02. During the same period in the previous year, the company posted $0.14 earnings per share. The business earned $47.20 million during the quarter, compared to analysts’ expectations of $44.11 million. Sucampo Pharmaceuticals’s quarterly revenue was up 60.0% on a year-over-year basis. On average, equities research analysts predict that Sucampo Pharmaceuticals Inc. will post $1.01 earnings per share for the current fiscal year.

Other large investors have made changes to their positions in the company. Globeflex Capital L P boosted its stake in shares of Sucampo Pharmaceuticals by 76.5% in the fourth quarter. Globeflex Capital L P now owns 65,588 shares of the biopharmaceutical company’s stock worth $1,134,000 after buying an additional 28,431 shares during the last quarter. Shell Asset Management Co. acquired a new stake in shares of Sucampo Pharmaceuticals during the fourth quarter worth approximately $1,324,000. Finally, Systematic Financial Management LP boosted its stake in shares of Sucampo Pharmaceuticals by 18.1% in the fourth quarter. Systematic Financial Management LP now owns 101,745 shares of the biopharmaceutical company’s stock worth $1,759,000 after buying an additional 15,590 shares during the last quarter.

Sucampo Pharmaceuticals, Inc is a global biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders. It generates revenue from product royalties, development milestone payments, product sales and clinical development activities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.